Elevance Health (ELV) Q2 FY2026 earnings: revenue $50.5 billion, up 1.4% on the year
Elevance Health, Inc. (ELV) reported revenue of $50.5 billion for Q2 FY2026, the quarter ended 30 June 2026, up 1.4% on the same quarter a year earlier. Net income was $1.5 billion, down 16.1% on the year, and diluted earnings per share $6.71. The figures are the company's own, from the 10-Q it filed with the SEC on 15 July 2026.
Revenue
$50.5 billion
+1.4% on the year · +0.6% on the quarter
Q3 FY2024Q2 FY2026
Operating margin
3.5%
4.9% a year earlier
Q3 FY2024Q2 FY2026
Net income
$1.5 billion
-16.1% on the year · -17.1% on the quarter
Q3 FY2024Q2 FY2026
Diluted EPS
$6.71
-13.1% on the year · -16.1% on the quarter
Q3 FY2024Q2 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 4 raised, 1 new.
Diluted EPS fell year over year: Diluted EPS was $6.71, against $7.72 a year earlier; adjusted diluted EPS was $7.45, against $8.84. The company cited favorable benefit expense performance and about $0.80 per share of net below-the-line benefit.
Health Benefits gain fell 42.6 percent: Health Benefits operating gain was $0.9 billion, against $1.6 billion. Operating margin was 2.1 percent against 3.8 percent, reflecting higher benefit expense and workforce and enterprise investments, partly offset by revenue growth.
Benefit expense ratio rose 80 basis points: Benefit expense ratio was 89.7 percent, up 80 basis points from 88.9 percent, driven by expected elevated medical cost trend in Government businesses, partly offset by Individual ACA.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q2 FY2026
Q1 FY2026
Q2 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
1,913
4,332
2,054
-55.8%
-6.9%
Capital expenditure
287
235
267
+22.1%
+7.5%
Free cash flow
1,626
4,097
1,787
-60.3%
-9.0%
Free cash flow margin
3.2%
8.2%
3.6%
Cash from investing
159
-1,642
-687
Cash from financing
-1,494
-2,515
-308
Depreciation and amortisation
366
354
380
+3.4%
-3.7%
Share-based compensation
75.0
55.0
81.0
+36.4%
-7.4%
Buybacks
234
1,124
378
-79.2%
-38.1%
Dividends paid
373
376
385
-0.8%
-3.1%
Dividend per share
$1.72
$1.72
$1.71
0.0%
+0.6%
Diluted shares, weighted
218m
220m
226m
-1.1%
-3.5%
Shares outstanding at period end
217m
217m
225m
-0.2%
-3.6%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q2 FY2026
Q1 FY2026
Q2 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
44,883
43,902
43,722
+2.2%
+2.7%
Non-controlling interest
139
140
129
-0.7%
+7.8%
Short-term borrowings
0.0
n/a
n/a
Debt
31,044
31,842
30,186
-2.5%
+2.8%
Other liabilities
50,372
49,943
47,901
+0.9%
+5.2%
Total liabilities and equity
126,438
125,827
121,938
+0.5%
+3.7%
Fixed assets
4,645
4,657
4,641
-0.3%
+0.1%
Goodwill
28,339
28,340
28,368
-0.0%
-0.1%
Intangible assets
10,983
11,093
11,490
-1.0%
-4.4%
Investments
26,978
27,019
26,385
-0.2%
+2.2%
Cash and equivalents
10,232
9,657
8,560
+6.0%
+19.5%
Other assets
45,261
45,061
42,494
+0.4%
+6.5%
Total assets
126,438
125,827
121,938
+0.5%
+3.7%
Questions
What was Elevance Health's revenue in Q2 FY2026?
Elevance Health (ELV) reported revenue of $50.5 billion for Q2 FY2026, the quarter ended 30 June 2026, up 1.4% on the same quarter a year earlier.
How much did Elevance Health earn in Q2 FY2026?
Net income for Q2 FY2026 was $1.5 billion, down 16.1% on the year, and diluted earnings per share $6.71.
When did Elevance Health report Q2 FY2026 results?
Elevance Health filed its 10-Q for the quarter ended 30 June 2026 with the SEC on 15 July 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 June 2026, filed 15 July 2026: the filing.